<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002354</url>
  </required_header>
  <id_info>
    <org_study_id>246D</org_study_id>
    <secondary_id>37</secondary_id>
    <nct_id>NCT00002354</nct_id>
  </id_info>
  <brief_title>A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients</brief_title>
  <official_title>One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give indinavir sulfate&#xD;
      plus stavudine to HIV-infected patients who have already been treated with zidovudine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>540</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or&#xD;
             isoniazid.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count 50 - 500 cells/mm3.&#xD;
&#xD;
          -  Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6&#xD;
             months use of another anti-HIV therapy other than d4T or any protease inhibitor.&#xD;
&#xD;
          -  No active opportunistic infection or visceral Kaposi's sarcoma.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients with hemophilia may be enrolled at discretion of investigator.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Symptomatic neuropathy.&#xD;
&#xD;
          -  Acute hepatitis.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretrovirals other than specified in protocol.&#xD;
&#xD;
          -  Chronic therapy for an active opportunistic infection.&#xD;
&#xD;
          -  Immunosuppressive therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any prior protease inhibitor or d4T.&#xD;
&#xD;
          -  Any nucleoside analogs within 2 weeks prior to study entry.&#xD;
&#xD;
          -  Investigational agents or immunomodulators within 30 days prior to study entry.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  More than 6 months of prior AZT unless intolerant, in which case more than 6 months of&#xD;
             another anti-HIV therapy (other than protease inhibitors or d4T).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merck &amp; Co Inc</name>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>088890100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Stavudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Indinavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

